Related Experiment Video

Updated: Jun 17, 2025

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers
10:49

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers

Published on: September 26, 2019

5.6K

CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer

Razia Rahman1, Muhammed H Rahaman2, Adrienne R Hanson1

  • 1Flinders University, College of Medicine and Public Health, Flinders Health and Medical Research Institute, Bedford Park, SA, Australia.

British Journal of Cancer
|August 8, 2024
PubMed
Abstract

Insights

Cyclin-dependent kinase 9 (CDK9) inhibitors like CDKI-73 show promise for treating prostate cancer by disrupting key cancer pathways. Combination therapy with BRD4 inhibitors may enhance effectiveness, especially in resistant cases.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Cyclin-dependent kinase 9 (CDK9) plays a crucial role in activating oncogenic transcriptional pathways in various cancers.
  • CDK9 inhibitors represent a significant advancement in cancer therapy development.
  • Prostate cancer, especially aggressive subtypes, presents a need for novel therapeutic strategies.

Purpose of the Study:

  • To evaluate the efficacy of the orally bioavailable CDK9 inhibitor, CDKI-73, in preclinical models of prostate cancer.
  • To elucidate the molecular mechanisms underlying CDKI-73's anti-cancer effects.
  • To explore combination therapies involving CDKI-73 for enhanced therapeutic outcomes.

Main Methods:

  • In vitro and in vivo studies using prostate cancer cell lines, xenograft models, and patient-derived organoids.
  • Assessment of CDK9 expression in clinical specimens via public datasets and immunohistochemistry.
  • Molecular profiling, including transcriptomic and epigenomic analyses, to understand CDKI-73's impact on cellular pathways.

Main Results:

  • CDKI-73 demonstrated significant inhibition of proliferation and induction of cell death in both androgen receptor (AR)-driven and AR-independent prostate cancer models.
  • CDKI-73 suppressed RNA polymerase II activity, leading to decreased expression of anti-apoptotic factor BCL-2 and other transcriptional defects.
  • CDKI-73 reprogrammed super-enhancers and suppressed key oncogenic pathways involving AR, MYC, and BRD4.
  • Combination of CDKI-73 with a BRD4 inhibitor (AZD5153) showed synergistic effects in patient-derived organoids and in vivo models.

Conclusions:

  • CDK9 inhibition effectively disrupts multiple oncogenic transcriptional pathways crucial for prostate cancer progression.
  • CDKI-73 exhibits significant therapeutic potential as a single agent and in combination therapies for prostate cancer.
  • CDKI-73 is particularly promising for treating aggressive and therapy-resistant forms of prostate cancer.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K
Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer08:34

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer

Published on: April 13, 2015

10.3K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
3.0K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.2K